Advertisement

Current Transplantation Reports

, Volume 3, Issue 4, pp 395–403 | Cite as

Vascularized Composite Allotransplantation: Medical Complications

  • Mehmet C. Uluer
  • Philip S. Brazio
  • Jhade D. Woodall
  • Arthur J. Nam
  • Stephen T. Bartlett
  • Rolf N. BarthEmail author
Vascularized Composite Allografts (L Cendales and R Barth, Section Editors)

Abstract

The objective of this review is to summarize the collective knowledge regarding the risks and complications in vascularized composite tissue allotransplantation (VCA), focusing on upper extremity and facial transplantation. The field of VCA has entered its second decade with an increasing experience in both the impressive good outcomes, as well as defining challenges, risks, and experienced poor results. The limited and selective publishing of negative outcomes in this relatively new field makes it difficult to conclusively evaluate outcomes of graft and patient survival and morbidities. Therefore, published data, conference proceedings, and communications were summarized in an attempt to provide a current outline of complications. These data on the medical complications of VCA should allow for precautions to avoid poor outcomes, data to better provide informed consent to potential recipients, and result in improvements in graft and patient outcomes as VCA finds a place as a therapeutic option for selected patients.

Keywords

Vascularized composite allotransplantation Vascularized composite allograft Facial transplantation Hand transplantation Complications Renal failure Rejection Malignancy Mortality 

Notes

Compliance with Ethical Standard

Conflict of Interest

Arthur Nam, Rolf Barth, Jhade Woodall, Mehmet Uluer, Philip Brazio, and Stephen Bartlet declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • of importance •• of major importance

  1. 1••.
    Jones JW et al. Successful hand transplantation. One-year follow-up. Louisville hand transplant team. N Engl J Med. 2000;343(7):468–73 .Early follow-up of the first successful hand VCA transplant demonstrating good immunologic and functional outcomes Google Scholar
  2. 2.
    Devauchelle B et al. First human face allograft: early report. Lancet. 2006;368(9531):203–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Khalifian S et al. Facial transplantation: the first 9 years. Lancet. 2014;384(9960):2153–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Petruzzo P et al. Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. Ann Surg. 2015;261(1):213–20.CrossRefPubMedGoogle Scholar
  5. 5•.
    Shores JT, Brandacher G, Lee WP. Hand and upper extremity transplantation: an update of outcomes in the worldwide experience. Plast Reconstr Surg. 2015;135(2):351e–60e. Contemporary summary of hand transplant outcomes and identified graft failures Google Scholar
  6. 6.
    Siemionow M, Gharb BB, Rampazzo A. Successes and lessons learned after more than a decade of upper extremity and face transplantation. Curr Opin Organ Transplant. 2013;18(6):633–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Lantieri L et al. Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes. Am J Transplant. 2011;11(2):367–78.CrossRefPubMedGoogle Scholar
  8. 8.
    Morelon E, Petruzzo P. Vascularized composite allotransplantation still remains an emerging field after 17 years. Curr Opin Organ Transplant. 2015;20(6):593–5.PubMedGoogle Scholar
  9. 9.
    Gordon CR et al. The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg. 2009;63(5):572–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Brazio, S.P., et al., Reconstructive Transplantation: What Can We Learn from Solid Organ Transplantation?, in The Science of Reconstructive Transplantation, G. Brandacher, Editor. 2015, Springer New York: New York, NY. p. 33–44.Google Scholar
  11. 11.
    Kaminska D et al. Significant infections after hand transplantation in a polish population. Transplant Proc. 2014;46(8):2887–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Roche NA et al. Complex facial reconstruction by vascularized composite allotransplantation: the first Belgian case. J Plast Reconstr Aesthet Surg. 2015;68(3):362–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Roche NA et al. Long-term multifunctional outcome and risks of face vascularized composite allotransplantation. J Craniomaxillofac Surg. 2015;26(7):2038–46.CrossRefGoogle Scholar
  14. 14.
    Petruzzo P et al. Clinicopathological findings of chronic rejection in a face grafted patient. Transplantation. 2015;99(12):2644–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Kermer C, Watzinger F, Oeckher M. Tongue transplantation: 10-month follow-up. Transplantation. 2008;85(4):654–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Cavadas PC, Ibanez J, Thione A. Surgical aspects of a lower face, mandible, and tongue allotransplantation. J Reconstr Microsurg. 2012;28(1):43–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Cavadas PC et al. Primary central nervous system posttransplant lymphoproliferative disease in a bilateral Transfemoral lower extremity transplantation recipient. Am J Transplant. 2015;15(10):2758–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Kanitakis J et al. Premalignant and malignant skin lesions in two recipients of vascularized composite tissue allografts (face, hands). Case Rep Transplant. 2015;2015:356459.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Petruzzo P et al. The international registry on hand and composite tissue transplantation. Transplantation. 2010;90(12):1590–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Weissenbacher A et al. Clinical and immunological update 15 Years after the first VCA—subsequent kidney transplantation after a bilateral hand transplant. Am J Transplant. 2015;15.Google Scholar
  21. 21.
    Pei G et al. A report of 15 hand allotransplantations in 12 patients and their outcomes in China. Transplantation. 2012;94(10):1052–9.CrossRefPubMedGoogle Scholar
  22. 22•.
    Kaufman CL et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant. 2012;12(4):1004–16 .This paper documents chronic vasculopathy appearing in a series of hand transplant patients. Experimental diagnostic imaging options are presented Google Scholar
  23. 23.
    Kanitakis J et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation. 2003;76(4):688–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Rahmel A. Vascularized composite allografts: procurement, allocation, and implementation. Curr Transplant Rep. 2014;1(3):173–82.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pomahac B, Diaz-Siso JR, Bueno EM. Evolution of indications for facial transplantation. J Plast Reconstr Aesthet Surg. 2011;64(11):1410–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Lemmens GM et al. Facial transplantation in a blind patient: psychologic, marital, and family outcomes at 15 months follow-up. Psychosomatics. 2015;56(4):362–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Carty MJ et al. A position paper in support of face transplantation in the blind. Plast Reconstr Surg. 2012;130(2):319–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Wo L, Bueno E, Pomahac B. Facial transplantation: worth the risks? A look at evolution of indications over the last decade. Curr Opin Organ Transplant. 2015;20(6):615–20.PubMedGoogle Scholar
  29. 29.
    Coffman KL, Gordon C, Siemionow M. Psychological outcomes with face transplantation: overview and case report. Curr Opin Organ Transplant. 2010;15(2):236–40.PubMedGoogle Scholar
  30. 30.
    Chandraker A et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014;14(6):1446–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Gordon CR, Abouhassan W, Avery RK. What is the true significance of donor-related cytomegalovirus transmission in the setting of facial composite tissue allotransplantation? Transplant Proc. 2011;43(9):3516–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Jowsey-Gregoire, S.G., et al., The Chauvet 2014 meeting report: psychiatric and psychosocial evaluation and outcomes of upper extremity grafted patients. Transplantation, 2015.Google Scholar
  33. 33.
    Renshaw A et al. Informed consent for facial transplantation. Transpl Int. 2006;19(11):861–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Lamparello BM et al. Face time: educating face transplant candidates. Eplasty. 2013;13:e36.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Coffman KL, Siemionow MZ. Ethics of facial transplantation revisited. Curr Opin Organ Transplant. 2014;19(2):181–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Sedaghati-nia A et al. Anaesthesia and intensive care management of face transplantation. Br J Anaesth. 2013;111(4):600–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Edrich T et al. Perioperative management of face transplantation: a survey. Anesth Analg. 2012;115(3):668–70.PubMedGoogle Scholar
  38. 38.
    Nelson JA et al. Intraoperative perfusion management impacts postoperative outcomes: an analysis of 682 autologous breast reconstruction patients. J Plast Reconstr Aesthet Surg. 2015;68(2):175–83.CrossRefPubMedGoogle Scholar
  39. 39.
    Kelly DA et al. Impact of intraoperative vasopressor use in free tissue transfer for head, neck, and extremity reconstruction. Ann Plast Surg. 2014;72(6):S135–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Blajchman MA. Transfusion immunomodulation or TRIM: what does it mean clinically? Hematology. 2005;10(Suppl 1):208–14.CrossRefPubMedGoogle Scholar
  41. 41.
    Opelz G et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation. 1997;63(7):964–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Houbiers JG et al. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion. 1997;37(2):126–34.CrossRefPubMedGoogle Scholar
  43. 43.
    Rohde JM et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014;311(13):1317–26.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Sarani B et al. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med. 2008;36(4):1114–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Lang RS et al. Anesthetic management in upper extremity transplantation: the Pittsburgh experience. Anesth Analg. 2012;115(3):678–88.PubMedGoogle Scholar
  46. 46.
    Rajan S et al. Anaesthetic management of bilateral hand transplantation. Indian J Anaesth. 2015;59(12):819–20.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Murphy BD, Zuker RM, Borschel GH. Vascularized composite allotransplantation: an update on medical and surgical progress and remaining challenges. J Plast Reconstr Aesthet Surg. 2013;66(11):1449–55.CrossRefPubMedGoogle Scholar
  48. 48.
    Hinojosa Perez R et al. Severe rhabdomyolysis after allogeneic transplantation of facial structures: a case report. Transplant Proc. 2010;42(8):3081–2.CrossRefPubMedGoogle Scholar
  49. 49.
    Schneider, M., et al., Vascularized Composite Allotransplantation: A Closer look at the Banff Working Classification. Transpl Int, 2016.Google Scholar
  50. 50.
    Mundinger GS, Drachenberg CB. Chronic rejection in vascularized composite allografts. Curr Opin Organ Transplant. 2014;19(3):309–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Mundinger GS et al. Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation. Transplantation. 2013;95(10):1204–10.CrossRefPubMedGoogle Scholar
  52. 52.
    Kanitakis J et al. Capillary thrombosis in the skin: a pathologic hallmark of severe/chronic rejection of human vascularized composite tissue allografts? Transplantation. 2016;100(4):954–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Kanitakis, J., et al., Chronic rejection in human vascularized composite allotransplantation (hand and face recipients): an update. Transplantation, 2016.Google Scholar
  54. 54.
    Barth RN et al. Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. Am J Transplant. 2011;11(7):1407–16.CrossRefPubMedGoogle Scholar
  55. 55.
    Petruzzo P et al. First human face transplantation: 5 years outcomes. Transplantation. 2012;93(2):236–40.CrossRefPubMedGoogle Scholar
  56. 56.
    Pomahac B et al. Three patients with full facial transplantation. N Engl J Med. 2012;366(8):715–22.CrossRefPubMedGoogle Scholar
  57. 57.
    Petruzzo P, Dubernard JM, The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl. 2011:247–53.Google Scholar
  58. 58.
    Hart A et al. Kidney. Am J Transplant. 2016;16(Suppl 2):11–46.CrossRefPubMedGoogle Scholar
  59. 59.
    Matas AJ et al. OPTN/SRTR 2013 annual data report: kidney. Am J Transplant. 2015;15(Suppl 2):1–34.CrossRefPubMedGoogle Scholar
  60. 60.
    Kim WR et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(Suppl 1):69–96.CrossRefPubMedGoogle Scholar
  61. 61.
    Kaufman CL et al. Monitoring and long-term outcomes in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2013;18(6):652–8.PubMedGoogle Scholar
  62. 62.
    Fischer S et al. Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2014;19(6):531–44.CrossRefPubMedGoogle Scholar
  63. 63.
    Diefenbeck M et al. Allograft vasculopathy after allogeneic vascularized knee transplantation. Transpl Int. 2011;24(1):e1–5.CrossRefPubMedGoogle Scholar
  64. 64.
    Kanitakis J et al. Graft vasculopathy in the skin of a human hand allograft: implications for diagnosis of rejection of vascularized composite allografts. Transpl Int. 2014;27(11):e118–23.CrossRefPubMedGoogle Scholar
  65. 65.
    Weissenbacher A et al. Antibody-mediated rejection in hand transplantation. Transpl Int. 2014;27(2):e13–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Weissenbacher A et al. Hand transplantation in its fourteenth year: the Innsbruck experience. Vascularized Composite Allotransplantation. 2014;1(1–2):11–21.CrossRefGoogle Scholar
  67. 67.
    Brazio PS et al. Regulatory T cells are not predictive of outcomes in a nonhuman primate model of vascularized composite allotransplantation. Transplantation. 2013;96(3):267–73.CrossRefPubMedGoogle Scholar
  68. 68.
    Meningaud JP et al. Procurement of total human face graft for allotransplantation: a preclinical study and the first clinical case. Plast Reconstr Surg. 2010;126(4):1181–90.CrossRefPubMedGoogle Scholar
  69. 69.
    Knoll BM et al. Infections following facial composite tissue allotransplantation—single center experience and review of the literature. Am J Transplant. 2013;13(3):770–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Gordon CR et al. Cytomegalovirus and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg. 2011;127(4):1515–23.CrossRefPubMedGoogle Scholar
  71. 71.
    Cavadas PC, Landin L, Ibanez J. Bilateral hand transplantation: result at 20 months. J Hand Surg Eur Vol. 2009;34(4):434–43.CrossRefPubMedGoogle Scholar
  72. 72.
    Bonatti H et al. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int. 2007;20(3):238–46.CrossRefPubMedGoogle Scholar
  73. 73.
    Chelmonski A, Jablecki J, Szajerka T. Insidious course of cytomegalovirus infection in hand transplant recipient: case report, diagnostics, and treatment. Transplant Proc. 2011;43(7):2827–30.CrossRefPubMedGoogle Scholar
  74. 74.
    Baldanti F et al. Sustained impairment of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cell response is responsible for recurrent episodes of disseminated HCMV infection in a D + R- hand transplant recipient. Cases J. 2008;1(1):155.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Hammond SP. Infections in composite tissue allograft recipients. Infect Dis Clin N Am. 2013;27(2):379–93.CrossRefGoogle Scholar
  76. 76.
    Broyles JM et al. Characterization, prophylaxis, and treatment of infectious complications in craniomaxillofacial and upper extremity allotransplantation: a multicenter perspective. Plast Reconstr Surg. 2014;133(4):543e–51e.CrossRefPubMedGoogle Scholar
  77. 77.
    Jiang HQ et al. Composite tissue allograft transplantation of cephalocervical skin flap and two ears. Plast Reconstr Surg. 2005;115(3):31e–5e .discussion 36e-37eCrossRefPubMedGoogle Scholar
  78. 78.
    Cavadas, P.C., Speed-update on world experience with clinical VCA. ASRT 3rd Biennial Meeting, 2012, Nov 15–17.Google Scholar
  79. 79.
    Seda IM, Zubair A, Brewer JD. Cutaneous malignancies in immunosuppressed organ transplant recipients. Skinmed. 2014;12(3):164–73.PubMedGoogle Scholar
  80. 80.
    Kasiske BL et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.CrossRefPubMedGoogle Scholar
  81. 81.
    Sheil AG et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993;25(1 Pt 2):1383–4.PubMedGoogle Scholar
  82. 82.
    Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998:147–58.Google Scholar
  83. 83.
    Barth RN et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. Transplantation. 2009;88(11):1242–50.CrossRefPubMedGoogle Scholar
  84. 84.
    Cendales L et al. Tacrolimus to belatacept conversion following hand transplantation: a case report. Am J Transplant. 2015;15(8):2250–5.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Barth R et al. Moderate rejection episode of face transplant after mTOR conversion to preserve renal function. Am J Transplant. 2015;15(S3):#1884.Google Scholar
  86. 86.
    Schneeberger S et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013;257(2):345.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87••.
    Dubernard J-M et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med. 2007;357(24):2451–60 .The first case of facial VCA transplantation reporting excellent early outcomes Google Scholar
  88. 89.
    Bernardon L et al. Bilateral hand transplantation: functional benefits assessment in five patients with a mean follow-up of 7.6 years (range 4-13 years). J Plast Reconstr Aesthet Surg. 2015;68(9):1171–83.CrossRefPubMedGoogle Scholar
  89. 90.
    Kaufman CL, Breidenbach W. World experience after more than a decade of clinical hand transplantation: update from the Louisville hand transplant program. Hand Clin. 2011;27(4):417–21.CrossRefPubMedGoogle Scholar
  90. 91.
    Brandacher G, Lee WP, Schneeberger S. Minimizing immunosuppression in hand transplantation. Expert Rev Clin Immunol. 2012;8(7):673–83 .quiz 684CrossRefPubMedGoogle Scholar
  91. 92.
    Sosin M et al. Eyelid transplantation: lessons from a total face transplant and the importance of blink. Plast Reconstr Surg. 2015;135(1):167e–75e.CrossRefPubMedGoogle Scholar
  92. 93.
    Singh M et al. Functional outcomes after bilateral hand transplantation: a 3.5-year comprehensive follow-up. Plast Reconstr Surg. 2016;137(1):185–9.CrossRefPubMedGoogle Scholar
  93. 94.
    Conference Proceedings. 12th Congress of the International Hand and Composite Tissue Allotransplantation Society, 2015.Google Scholar
  94. 95.
    Kueckelhaus, M., et al., Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transpl Int, 2015.Google Scholar
  95. 96.
    Barret JP. From partial to full-face transplantation: total ablation and restoration, a change in the reconstructive paradigm. Int J Surg. 2014;12(2):109–12.CrossRefPubMedGoogle Scholar
  96. 97.
    Shanmugarajah K, Hettiaratchy S, Butler PE. Facial transplantation. Curr Opin Otolaryngol Head Neck Surg. 2012;20(4):291–7.CrossRefPubMedGoogle Scholar
  97. 98.
    Morales I, D.A., Kaufman C, et al. Session B6: What can we do when complications ensue? Round table discussion with case illustrations. in IHCTAS 2013: 11th Meeting of the International Hand and Composite Tissue Allotransplantation Society. 2013. Wroclaw, Poland.Google Scholar
  98. 99.
    Breidenbach WC et al. A statistical comparative assessment of face and hand transplantation outcomes to determine whether either meets the standard of care threshold. Plast Reconstr Surg. 2016;137(1):214e–22e.CrossRefPubMedGoogle Scholar
  99. 100.
    Cendales LC, Rahmel A, Pruett TL. Allocation of vascularized composite allografts: what is it? Transplantation. 2012;93(11):1086–7.CrossRefPubMedGoogle Scholar
  100. 101.
    Health R. D.O.H. Services administration, and S. Human, Organ procurement and transplantation network. Final rule. Fed Regist. 2013;78(128):40033–42.Google Scholar
  101. 102.
    Schneeberger S et al. Vascularized composite allotransplantation: a member of the transplant family? Transplantation. 2012;93(11):1088–91.CrossRefPubMedGoogle Scholar
  102. 103.
    Cendales L et al. Implementation of vascularized composite allografts in the United States: recommendations from the ASTS VCA ad hoc committee and the executive committee. Am J Transplant. 2011;11(1):13–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  • Mehmet C. Uluer
    • 1
  • Philip S. Brazio
    • 1
  • Jhade D. Woodall
    • 1
  • Arthur J. Nam
    • 1
  • Stephen T. Bartlett
    • 1
  • Rolf N. Barth
    • 1
    Email author
  1. 1.Department of Surgery, Division of TransplantationUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations